Peter Blanken

2.3k citations

66 papers · 1.6k indexed · h-index 21

Impact in

Toxicology top 1%
- Forensic Toxicology and Drug Analysis
Epidemiology top 5%
- Substance Abuse Treatment and Outcomes
- HIV, Drug Use, Sexual Risk

Papers in ⓘ

Epidemiology 32
- Substance Abuse Treatment and Outcomes 29
Psychiatry and Mental health 19
- Schizophrenia research and treatment 16

Co-authors: Wim van den Brink (34 shared papers)Vincent M. Hendriks (31 shared papers)Jan M. van Ree (18 shared papers)Marlies A.E. Marissen (4 shared papers)Ingmar H. A. Franken (4 shared papers)Andrew J. Waters (1 shared paper)E. van der Schee (2 shared papers)Marcel G. W. Dijkgraaf (3 shared papers)
Journals: Drug and Alcohol Dependence (10 papers)BMC Psychiatry (5 papers)Addiction (4 papers)European Addiction Research (4 papers)Pharmacogenomics (3 papers)
Partner nations: Netherlands United States Germany

In The Last Decade

Peter Blanken

61 papers receiving 1.5k citations

Peers

Countries citing papers authored by Peter Blanken

Since Specialization

Citations

This map shows the geographic impact of Peter Blanken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Blanken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Blanken more than expected).

Fields of papers citing papers by Peter Blanken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Blanken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Blanken. The network helps show where Peter Blanken may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Blanken, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Blanken Line = papers co-authored together Peter Blanken links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 66 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Attentional bias predicts heroin relapse following treatment Addiction ·Marlies A.E. Marissen, Ingmar H. A. Franken, Andrew J. Waters, Peter Blanken, Wim van den Brink, Vincent M. Hendriks	2006	217
2	Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials BMJ ·Marcel G. W. Dijkgraaf, Bart P. van der Zanden, Corianne A.J.M. de Borgie, Peter Blanken, Jan M. van Ree, Wim van den Brink	2005	103
3	Cue Exposure Therapy for the Treatment of Opiate Addiction: Results of a Randomized Controlled Clinical Trial Psychotherapy and Psychosomatics ·Marlies A.E. Marissen, Ingmar H. A. Franken, Peter Blanken, Wim van den Brink, Vincent M. Hendriks	2007	87
4	Heroin-assisted Treatment (HAT) a Decade Later: A Brief Update on Science and Politics Journal of Urban Health ·Benedikt Fischer, Eugenia Oviedo‐Joekes, Peter Blanken, Christian Haasen, Jürgen Rehm, Martin T. Schechter, John Strang, Wim van den Brink	2007	79
5	Treatment of adolescents with a cannabis use disorder: Main findings of a randomized controlled trial comparing multidimensional family therapy and cognitive behavioral therapy in The Netherlands Drug and Alcohol Dependence ·Vincent M. Hendriks, E. van der Schee, Peter Blanken	2011	74
6	Reaching the Unreached: Targeting Hidden IDU Populations with Clean Needles via Known User Groups Journal of Psychoactive Drugs ·Jean‐Paul Grund, Peter Blanken, NICO F. P. ADRIAANS, Charles D. Kaplan, Cas Barendregt, Mart Meeuwsen	1992	67
7	Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial The Lancet ·Mascha Nuijten, Peter Blanken, Ben van de Wetering, Bastiaan Nuijen, Wim van den Brink, Vincent M. Hendriks	2016	60
8	The role of stabilizing and communicating symptoms given overlapping communities in psychopathology networks Scientific Reports ·Tessa F. Blanken, Marie K. Deserno, Jonas Dalege, Denny Borsboom, Peter Blanken, G.A. Kerkhof, Angélique O. J. Cramer	2018	57
9	Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: A comprehensive narrative overview of English-language studies International Journal of Drug Policy ·Benedikt Fischer, Peter Blanken, Dartiu Xavier da Silveira, Andréa Donatti Gallassi, Elliot M. Goldner, Jürgen Rehm, Mark Tyndall, Evan Wood	2015	56
10	Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population Drug and Alcohol Dependence ·Bart P. van der Zanden, Marcel G. W. Dijkgraaf, Peter Blanken, Corianne A.J.M. de Borgie, Jan M. van Ree, Wim van den Brink	2005	55
11	Drug Sharing and HIV Transmission Risks: The Practice of Frontloading in the Dutch Injecting Drug User Population Journal of Psychoactive Drugs ·Jean‐Paul Grund, Charles D. Kaplan, NICO F. P. ADRIAANS, Peter Blanken	1991	55
12	Outcome of long‐term heroin‐assisted treatment offered to chronic, treatment‐resistant heroin addicts in the Netherlands Addiction ·Peter Blanken, Vincent M. Hendriks, Jan M. van Ree, Wim van den Brink	2009	53
13	Heroin-assisted treatment in the Netherlands: History, findings, and international context European Neuropsychopharmacology ·Peter Blanken, Wim van den Brink, Vincent M. Hendriks, Ineke A. Huijsman, Marjolein G. Klous, Elisabeth J. Rook, Jennifer S. Wakelin, Cas Barendrecht, Jos H. Beijnen, Jan M. van Ree	2010	51
14	Heroin self-administration by means of ‘chasing the dragon’: pharmacodynamics and bioavailability of inhaled heroin European Neuropsychopharmacology ·Vincent M. Hendriks, Wim van den Brink, Peter Blanken, Ingrid J. Bosman, Jan M. van Ree	2001	46
15	Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial The Lancet Psychiatry ·Ernst Noordraven, André I. Wierdsma, Peter Blanken, Anthony F. T. Bloemendaal, Anton B. P. Staring, Cornelis L. Mulder	2017	35
16	Matching adolescents with a cannabis use disorder to multidimensional family therapy or cognitive behavioral therapy: Treatment effect moderators in a randomized controlled trial Drug and Alcohol Dependence ·Vincent M. Hendriks, E. van der Schee, Peter Blanken	2012	33
17	A dual perspective on first-session therapeutic alliance: strong predictor of youth mental health and addiction treatment outcome European Child & Adolescent Psychiatry ·Patty van Benthem, Renske Spijkerman, Peter Blanken, Marloes Kleinjan, Robert Vermeiren, Vincent M. Hendriks	2020	32
18	Matching of treatment‐resistant heroin‐dependent patients to medical prescription of heroin or oral methadone treatment: results from two randomized controlled trials Addiction ·Peter Blanken, Vincent M. Hendriks, Maarten W.J. Koeter, Jan M. van Ree, Wim van den Brink	2004	31
19	Treatment of crack-cocaine dependence with topiramate: A randomized controlled feasibility trial in The Netherlands Drug and Alcohol Dependence ·Mascha Nuijten, Peter Blanken, Wim van den Brink, Vincent M. Hendriks	2014	28
20	Personality as a risk factor for illicit opioid use and a protective factor for illicit opioid dependence Drug and Alcohol Dependence ·Eline R. Zaaijer, Jessica Bruijel, Peter Blanken, Vincent M. Hendriks, Maarten W.J. Koeter, Mary Jeanne Kreek, Jan Booij, Anna E. Goudriaan, Jan M. van Ree, Wim van den Brink	2014	24

About Peter Blanken

Peter Blanken is a scholar working on Epidemiology, Psychiatry and Mental health, Clinical Psychology, Public Health, Environmental and Occupational Health and Cellular and Molecular Neuroscience, having authored 66 papers that have together received 1.6k indexed citations. Recurring topics across this work include Substance Abuse Treatment and Outcomes (29 papers), Schizophrenia research and treatment (16 papers), Opioid Use Disorder Treatment (13 papers), Neurotransmitter Receptor Influence on Behavior (12 papers), Child and Adolescent Psychosocial and Emotional Development (8 papers), Cannabis and Cannabinoid Research (8 papers), Forensic Toxicology and Drug Analysis (8 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (6 papers). The work is most often cited by research in Toxicology (138 citations), Epidemiology (671 citations), Experimental and Cognitive Psychology (249 citations), Applied Psychology (90 citations) and Cellular and Molecular Neuroscience (315 citations). Peter Blanken has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Wim van den Brink, Vincent M. Hendriks, Jan M. van Ree, Marlies A.E. Marissen, Ingmar H. A. Franken, Andrew J. Waters, E. van der Schee, Marcel G. W. Dijkgraaf, Corianne A.J.M. de Borgie and Charles D. Kaplan. Their work appears in journals such as Drug and Alcohol Dependence, BMC Psychiatry, Addiction, European Addiction Research and Pharmacogenomics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact